GH Research and Charts

GH - Guardant Health Inc (Healthcare: Diagnostics & Research)

Projected Earnings Date: 2025-10-29 (Delayed quote data 2025-09-12)

Last 54.90	Change ⇓ -1.67 (-2.96%)	Volume 2,648,290
	Open 55.33	High 55.63	Low 53.67

8EMA (Daily) 59.93	40EMA (Daily) 55.92	50EMA (Daily) 54.67	STO (Daily) 29.139	MACD Hist (Daily) -2.511
8EMA (Weekly) 56.433	40EMA (Weekly) 45.99	50EMA (Weekly) 44.04	STO (Weekly) 82.682	MACD Hist (Weekly) 1.603


Company Profile
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company?s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.